| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIP1 |
| Uniprot No | Q9Y3R0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1128aa |
| 氨基酸序列 | MIAVSFKCRCQILRRLTKDESPYTKSASQTKPPDGALAVRRQSIPEEFKGSTVVELMKKEGTTLGLTVSGGIDKDGKPRVSNLRQGGIAARSDQLDVGDYIKAVNGINLAKFRHDEIISLLKNVGERVVLEVEYELPPVSVQGSSVIFRTVEVTLHKEGNTFGFVIRGGAHDDRNKSRPVVITCVRPGGPADREGTIKPGDRLLSVDGIRLLGTTHAEAMSILKQCGQEAALLIEYDVSVMDSVATASGPLLVEVAKTPGASLGVALTTSMCCNKQVIVIDKIKSASIADRCGALHVGDHILSIDGTSMEYCTLAEATQFLANTTDQVKLEILPHHQTRLALKGPDHVKIQRSDRQLTWDSWASNHSSLHTNHHYNTYHPDHCRVPALTFPKAPPPNSPPALVSSSFSPTSMSAYSLSSLNMGTLPRSLYSTSPRGTMMRRRLKKKDFKSSLSLASSTVGLAGQVVHTETTEVVLTADPVTGFGIQLQGSVFATETLSSPPLISYIEADSPAERCGVLQIGDRVMAINGIPTEDSTFEEASQLLRDSSITSKVTLEIEFDVAESVIPSSGTFHVKLPKKHNVELGITISSPSSRKPGDPLVISDIKKGSVAHRTGTLELGDKLLAIDNIRLDNCSMEDAVQILQQCEDLVKLKIRKDEDNSDEQESSGAIIYTVELKRYGGPLGITISGTEEPFDPIIISSLTKGGLAERTGAIHIGDRILAINSSSLKGKPLSEAIHLLQMAGETVTLKIKKQTDAQSASSPKKFPISSHLSDLGDVEEDSSPAQKPGKLSDMYPSTVPSVDSAVDSWDGSAIDTSYGTQGTSFQASGYNFNTYDWRSPKQRGSLSPVTKPRSQTYPDVGLSYEDWDRSTASGFAGAADSAETEQEENFWSQALEDLETCGQSGILRELEEKADRRVSLRNMTLLATIMSGSTMSLNHEAPTPRSQLGRQASFQERSSSRPHYSQTTRSNTLPSDVGRKSVTLRKMKQEIKEIMSPTPVELHKVTLYKDSDMEDFGFSVADGLLEKGVYVKNIRPAGPGDLGGLKPYDRLLQVNHVRTRDFDCCLVVPLIAESGNKLDLVISRNPLASQKSIDQQSLPGDWSEQNSAFFQQPSHGGNLETREPTNTL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于GRIP1重组蛋白的参考文献及其摘要内容的简要概括：
---
1. **"GRIP: A Synaptic PDZ Domain-Containing Protein that Interacts with AMPA Receptors"**
- **作者**: Dong H. et al. (1997)
- **摘要**: 该研究首次克隆并鉴定了GRIP1(Glutamate Receptor Interacting Protein 1)，发现其通过PDZ结构域与AMPA受体亚基GluA2的C端相互作用，提示其在突触后膜受体锚定中的功能。重组GRIP1蛋白被用于体外结合实验，证实其与受体直接结合。
2. **"PDZ Domains of GRIP Target AMPA Receptors to Synaptic Sites"**
- **作者**: Bruckner K. et al. (1999)
- **摘要**: 利用重组GRIP1蛋白的PDZ结构域进行结构功能分析，发现其多个PDZ结构域协同作用，调控AMPA受体在神经元中的定位和聚集，揭示GRIP1在突触组织中的支架作用。
3. **"GRIP1 Controls Synaptic Strength by Stabilizing AMPA Receptors at the Postsynaptic Density"**
- **作者**: Takamiya K. et al. (2004)
- **摘要**: 通过过表达重组GRIP1蛋白及突变体，证明GRIP1通过稳定突触后AMPA受体的膜定位，调节长时程增强(LTP)，影响突触可塑性和学习记忆功能。
4. **"Phosphorylation of GRIP1 Regulates Its Interaction with AMPA Receptors"**
- **作者**: Chung H.J. et al. (2000)
- **摘要**: 研究利用重组GRIP1蛋白探讨磷酸化修饰对其功能的影响，发现特定位点的磷酸化可减弱其与GluA2的结合能力，提示GRIP1的活性受激酶信号通路动态调控。
---
以上文献均涉及GRIP1重组蛋白在受体互作、结构域功能、突触调控及翻译后修饰中的关键研究，为理解其神经生物学机制提供了基础。
GRIP1 (Glutamate Receptor Interacting Protein 1) is a scaffolding protein primarily involved in the trafficking, clustering, and synaptic anchoring of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are critical for excitatory neurotransmission in the central nervous system. Discovered in the late 1990s, GRIP1 contains multiple PDZ domains that mediate protein-protein interactions, enabling it to act as a molecular hub. It binds to the C-terminal tails of AMPA receptor subunits (GluA2/3) and other synaptic proteins, facilitating their localization at postsynaptic membranes.
Beyond its role in receptor stabilization, GRIP1 participates in neuronal development, synaptic plasticity, and dendritic spine morphogenesis. Studies suggest its involvement in intracellular signaling pathways, including interactions with Eph receptors, β-catenin, and liprin-α, linking synaptic activity to structural and functional adaptations. Dysregulation of GRIP1 has been implicated in neurological disorders such as autism spectrum disorders, schizophrenia, and epilepsy, underscoring its importance in maintaining synaptic homeostasis.
Recombinant GRIP1 proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to study its biochemical properties, domain-specific functions, and interaction networks in vitro. These purified proteins serve as tools for pull-down assays, crystallography, and drug screening. Researchers also utilize GRIP1 variants to explore mutations affecting synaptic targeting or to disrupt specific binding interfaces, advancing our understanding of AMPA receptor regulation and potential therapeutic strategies for neuropsychiatric diseases. Its modular structure and multifunctional nature make GRIP1 a key focus in synapse biology and neuropharmacology.
×
